Thermo Fisher Scientific Inc (TMO): Price and Financial Metrics
Thermo Fisher Scientific Inc (TMO)
Today's Latest Price: $517.22 USD
Updated Jan 21 1:17pm
Add TMO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 64 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
TMO Stock Summary
- With a market capitalization of $204,445,544,925, Thermo Fisher Scientific Inc has a greater market value than 99.19% of US stocks.
- Thermo Fisher Scientific Inc's stock had its IPO on September 1, 1987, making it an older stock than 91.54% of US equities in our set.
- Price to trailing twelve month operating cash flow for TMO is currently 29.79, higher than 83.87% of US stocks with positive operating cash flow.
- If you're looking for stocks that are quantitatively similar to Thermo Fisher Scientific Inc, a group of peers worth examining would be KO, ABT, T, PEP, and PDD.
- TMO's SEC filings can be seen here. And to visit Thermo Fisher Scientific Inc's official web site, go to www.thermofisher.com.
TMO Stock Price Chart Interactive Chart >
TMO Price/Volume Stats
| Current price | $517.22 | 52-week high | $532.57 |
| Prev. close | $515.84 | 52-week low | $250.21 |
| Day low | $512.75 | Volume | 613,402 |
| Day high | $520.00 | Avg. volume | 1,756,110 |
| 50-day MA | $475.14 | Dividend yield | 0.17% |
| 200-day MA | $414.58 | Market Cap | 204.99B |
Thermo Fisher Scientific Inc (TMO) Company Bio
Thermo Fisher Scientific provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company was founded in 1956 and is based in Waltham, Massachusetts.
TMO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $517.22 | $248.96 | -52% |
We started the process of determining a valid price forecast for Thermo Fisher Scientific Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Thermo Fisher Scientific Inc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Thermo Fisher Scientific Inc, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 5.96; that's higher than 57.66% of US stocks in the Healthcare sector that have positive free cash flow.
- 91% of the company's capital comes from equity, which is greater than 74.38% of stocks in our cash flow based forecasting set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -53% |
| 1% | -52% |
| 2% | -52% |
| 3% | -51% |
| 4% | -51% |
| 5% | -50% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as TMO, try RGEN, A, IART, MD, and BIO.
Loading social stream, please wait...